.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after an average follow-up of 11 months, people along with metastatic stomach lumps that acquired biomarker-matched treatments based on spreading growth DNA profiling revealed a more significant clinical perk than those obtaining unequaled therapy.